Nutraceutix Extends Reach of BIO-tract Patents to 33 Countries
The probiotics are uniquely formulated for targeted delivery in the intestine.
Nutraceutix Inc. (Redmond, WA) has announced that its range of BIO-tract probiotics has earned patents in more than 30 countries.
BIO-tract patented probiotics are formulated to protect against harsh stomach acid, ensuring more of the live organisms are able to reach the upper and lower intestinal tract, where they can offer the most health benefit. Fluids in the stomach activate the formation of a protective layer which shields the live organisms from gastric acid. Once in the intestinal tract, the protective layer releases the bacteria from the tablet core.
The products also employ Nutraceutix’s patented LiveBac processing technique, which extends the product’s shelf life, even when stored at room temperature.
The primary BIO-tract patent is its “Delivery System for Biological Component,” and it is held in the U.S., Australia, Canada, Singapore, Japan, Hong Kong, Republic of Korea, People’s Republic of China, the Russian Federation, and in the European Patent Convention (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, The Netherlands, Portugal, Slovakia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom). Additional patents in the U.S. and Canada are pending.
